The current state of molecular profiling in gastrointestinal malignancies. [Review] 

 -  2022 
<br/><br/>Available online through MWHC library: 2006 - present 
<br/><br/> This is a review of the current state of molecular profiling in gastrointestinal (GI) cancers and what to expect from this evolving field in the future. Individualized medicine is moving from broad panel testing of numerous genes or gene products in tumor biopsy samples, identifying biomarkers of prognosis and treatment response, to relatively noninvasive liquid biopsy assays, building on what we have learned in our tumor analysis and growing into its own evolving predictive and prognostic subspecialty. Hence, the field of GI precision oncology is exploding, and this review endeavors to summarize where we are now in preparation for the journey ahead. Copyright © 2022. The Author(s). 
<br/><br/><br/>English 
<br/><br/><label>ISSN: </label>1745-6150 
<br/><br/><label>Standard No.: </label>10.1186/s13062-022-00322-0 [doi] 10.1186/s13062-022-00322-0 [pii] 
<br/><br/><label>Subjects--Topical Terms: </label><br/>*Gastrointestinal Neoplasms<br/>*Precision Medicine<br/>Biomarkers, Tumor/ge [Genetics]<br/>Gastrointestinal Neoplasms/di [Diagnosis]<br/>Gastrointestinal Neoplasms/ge [Genetics]<br/>High-Throughput Nucleotide Sequencing<br/>Humans<br/>Liquid Biopsy<br/>Mutation
<br/><br/><label>Subjects--Geographic Terms: </label><br/>MedStar Washington Hospital Center
<br/><br/><label>Index Terms--Occupation: </label><br/>Hematology & Oncology Fellowship<br/>Hematology & Oncology Fellowship<br/>Hematology/Oncology Fellowship<br/>MedStar Georgetown University Hospital/MedStar Washington Hospital Center
<br/><br/><label>Index Terms--Function: </label><br/>Journal Article<br/>Review